EndoSphere has developed a weight-loss device, called the “SatiSphere™” that is placed in the duodenum and effectively slows the passage of food thereby causing increased satiety signaling to the brain. EndoSphere’s technology takes advantage of the fixed shape of the duodenum, thereby achieving ‘self-anchoring’. This is a significant element of EndoSphere’s intellectual property, and has the added benefit of permitting the procedure to be completed quickly, and with less skill. Eleven patients were enrolled in a Phase I Clinical Trial, conducted at a hospital in Mexico. The trial was considered successful with a mean excess weight-loss of 12%. The Company plans to develop, test and commercialize in European clinics in the second half of 2011.
EndoSphere’s President and CEO is James McKinley. He has vast experience as a serial medical device entrepreneur, and has founded or led numerous start-ups. He was the acting CEO of Target during its formative years, before it was purchased by Boston Scientific.
Stephen Haynes serves on the board of this company.